Ann-Cathrin Volz works as Application Specialist for BMG LABTECH with specific focus on cell-based assays. After her graduation in Nutritional Sciences at the University of Hohenheim she completed her PhD and a Postdoc in the field of Tissue Engineering. In her position, she can draw on her experience in cell culture and related microplate-based assays to support customers in assay optimisation for existing and emerging applications.
Also part of BMG′s Application Specialist team, Martin Mangold focusses on enzyme-based assays. He graduated in biology followed by a Master of Science in the field of drug research. He went on and completed his PhD in the field of medicinal chemistry at the University of Bonn. Now he uses his knowledge of enzyme-based and drug screening microplate assays to support customers with their applications and assay optimisation.
Tatiana Tiago is the Product Manager at Creoptix with over 8 years’ experience in pharma and biotech industry. Her background in molecular biology has given her a wide understanding of binding interaction analysis including label-based and label-free technologies. Tatiana holds a degree in in Medical Molecular Biology from the University of Westminster and a PhD in Neuroscience from the University of Modena and Reggio Emilia. Recently, Tatiana’s focus is to help life-science scientist understand GCI and optimize the label-free WAVEsystem enabling them to accelerate drug discovery.
Trevor Askwith is a cell biologist and biochemist with over 10 years’ experience of small-molecule drug discovery research. He began is drug discovery career as a cell biologist at Novartis where and has more recently worked in academic drug discovery running leading the Assay Development and Screening in the Drug Discovery Group at UCL. Trevor is now the Group Leader for Assay Biology a Domainex responsible of the biophysics, biochemistry and cell biology departments.
Dr Tom Mander has nearly 30 years of small molecule drug discovery and translational research experience in both scientific and commercial roles. After graduating and working at Amersham International plc developing radioimmunoassays, he completed his DPhil studies with Professor John Morris into the roles of microglial cells at the Department of Human Anatomy, University of Oxford in 1992. Tom joined Domainex in April 2015 as Chief Operating Officer to oversee the scientific service operations and business development activities of the company. During his time in this role, he has established a broad portfolio of pharma, biotech, academic and patient foundation clients both in the UK and overseas, launched several new services and has overseen the growth of the company. In April 2020, he took over as Chief Executive Officer after the retirement of Dr Trevor Perrior.
瑞士Creoptix，拥有基于光栅耦合干涉技术（Grating-Coupled Interferometry ，GCI）的光学生物传感器专利，以及外置的微流体的独特设计和Google公司研发的自动化软件。致力于提供高质量的动力学数据，拥有业内最灵敏准确的WAVEsystem无标记分子相互作用仪，使全球生物科学研究者可以做以前不可能做的事情，看到以前看不见的数据。凭借突破性的创新，避开了SPR的局限性，突破无标记技术的局限。
Bio-Gene Technology Ltd.
热线：176 2009 3784
香港 北京 上海 广州 成都 武汉 济南